Combination Therapy Key to Fighting Bacterial Infections

by Karen Buckheit

Current antibiotic treatments include using one or two drugs to fight an infection, and these treatments are becoming less and less effective as bacteria and other pathogens continue to develop and spread resistance mechanisms against them.

October 4, 2018 | Read More

The State of Neisseria Gonorrhoeae Infection: Overcoming Last Resort Antibiotics

by Karen Buckheit

Through intensive research and development efforts in the area of topical microbicides for the prevention of sexually transmitted HIV and bacterial and fungal vaginosis infections, ImQuest BioSciences has gained significant expertise in many STIs, including Neisseria gonnorrhoeae.

June 7, 2018 | Read More

Vector Born Diseases: Prevalence and Prevention

by Tracy Hartman

With the rise in vector-born diseases and the spread of insect populations to new habitats worldwide, new therapeutic and prevention products are needed to protect infected individuals against emerging diseases.

May 31, 2018 | Read More

Drug Resistant Bacteria are Reaching "Nightmare" Status

by Karen Buckheit, Director Microbiology and Prevention Services

Contact us to learn more and discuss ways that we can help the world wake up from the nightmare of untreatable bacterial infections.

May 2, 2018 | Read More

The critical unmet need for novel antiviral drugs to combat epidemic influenza

by Robert W. Buckheit III

Until a universal flu vaccine is developed, vaccination and rapid treatment with anti-influenza drugs are the most effective means of preventing serious illness. There is a pressing need for more effective therapeutic products against influenza and other respiratory viruses.

January 23, 2018 | Read More

International HBV Meeting: Primary Cell Screening Assays, HAV Outbreak, and HBV Stock Production

by Robert W. Buckheit III, Ph.D.

We appreciated the opportunity to meet with our colleagues in the field of antiviral and HBV development at the International HBV Meeting last week and present on our PHH screening and HBV Virus Production methods.

September 13, 2017 | Read More

Drug-Resistant Gonorrhea: The Search for New Antibiotics to Fight an Emerging Problem

by Robert Buckheit III

Due to a combination factors, there is a possibility of widespread resistance to all known antibiotics on the market to treat gonorrhea.

July 19, 2017 | Read More

Virology Updates: Influenza and Yellow Fever on the Rise

by Robert Buckheit III

Influenza incidence on the rise, and yellow fever outbreak in Brazil highlight need for new antiviral therapies. Contact us to learn more about how we can assist your anti-infectious product development.

February 1, 2017 | Read More

Pan Resistant Bacteria: How Scared Should We Be?

by Robert W. Buckheit III

The threat of antibiotic resistance continues to grow, and more research and development is vital to combating the spread of "superbugs".

January 18, 2017 | Read More

Lessons from HIV Research for Prevention: How to Prevent Mucosal Transmission of HIV

by Robert W. Buckheit, Jr.

Members of ImQuest BioSciences research team traveled to the HIV Research for Prevention meetings in Chicago last week to hear updates on research on topical microbicides and preventative pharmaceutical agents. Many sessions at the conference focused on initial events that result in productive infection following exposure to HIV. Currently, significant progress is being made throughout […]

October 27, 2016 | Read More

Multi-marker Analysis of Anti-HBV Products Utilizing Primary Human Hepatocytes

by Robert W. Buckheit III

ImQuest BioSciences has developed and optimized a novel antiviral screening assay for hepatitis B virus (HBV) in primary human hepatocytes.

October 11, 2016 | Read More

Zika Virus Insights: News and Updated Zika Services

by Robert Buckheit III

ImQuest BioSciences has the tools to advance your Zika virus development program, with a suite of in vitro assays including anti-Zika virus screening assays as well as assays to evaluate promising drug candidates.

September 20, 2016 | Read More

Anti-Dengue antibodies enhance Zika virus infection

by Robert W. Buckheit III

As part of our ViroSENS program, ImQuest BioSciences has established an anti-Zika virus cytoprotection assay for multiple strains of Zika virus in multiple cell types.

June 28, 2016 | Read More

Are We At the End of the Road for Known Antibiotics?

by Robert W. Buckheit III

This week, public health authorities in the United States reacted with alarm to the discovery of colistin-resistant bacteria in an infected woman in Pennsylvania. The discovery highlights the need for increased resources and research to discover and develop novel, next generation antibiotics.

June 14, 2016 | Read More

Is it a Poison, or is it a Life-Saving Drug?

by Bobby Buckheit, Karen Buckheit and Tracy Hartman

ImQuest BioSciences has developed the ToxiSENS program to rapidly and efficiently analyze the in vitro and ex vivo toxicity of potential drugs, and answer the age old question in drug development: is this a potential drug, or is this simply a poison?

May 26, 2016 | Read More

Come Visit Us At the 29th ICAR Meeting in San Diego!

by Robert W. Buckheit III

The 29th International Conference on Antiviral Research begins on Sunday April 17th. ImQuest looks forward to connecting with our unique clients and helping drive the development of novel antivirals.

April 13, 2016 | Read More

Come Visit us at the Society of Toxicology Conference in New Orleans!

by Robert Buckheit, Jr.

At the ImQuest booth in New Orleans we will discuss our diverse capabilities to assess the toxicity of new products, and ways that we help our clients save time and resources.

March 9, 2016 | Read More

Find a Diamond in the Rough: Utilizing Formulation to Maximize Your Pharmaceutical Product's Potential

by Robert Buckheit III

ImQuest BioSciences developed the ImQuestSUCCESS platform to analyze the efficacy, toxicity and pharmaceutical properties of a potential new drug candidate early in the lead development process.

February 24, 2016 | Read More

Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance

by Robert Buckheit III

We at ImQuest BioSciences are dedicated to providing services to pharmaceutical and academic groups that have a vested interest in the development of novel antimicrobial agents.

February 16, 2016 | Read More

Happy birthday to us, happy birthday to us, happy birthday ImQuest BioSciences, happy birthday to us!

by Robert Buckheit Jr.

We celebrates twelve years of being in business, and are focused on relationship building and providing the highest level of services to our clients. We thank our many unique clients for their support, and hope for continued SUCCESS in 2016 and beyond.

February 10, 2016 | Read More

Optimization of Assay to Analyze Biofilm development and Identify Antimicrobial Agents

by Robert Buckheit III

The ImQuest scientific team has optimized a high-throughput protocol to study biofilm development and the effect of antimicrobial agents on biofilm formation, available in the resource library.

February 3, 2016 | Read More

Growing Threat of Zika Virus Highlights Need for Improved Flavivirus Therapeutics

by Robert W. Buckheit III, PhD, Director, Immunology and Flow Cytometry Services

Efforts to combat flaviviruses, such as Dengue, Chikungunya and Zika, have intensified in Brazil, as the incidence rate of Zika virus has steadily increased. ImQuest BioSciences has the capability to evaluate the efficacy and toxicity of novel products against a range of flaviviruses.

January 25, 2016 | Read More

The World Needs New Antibiotics

by Robert Buckheit, Jr., Ph.D., President and CSO

We believe the development of new antimicrobial agents will be a critical need in pharmaceutical drug development for the foreseeable future. As drug-resistant bacteria strains continue to emerge and the antibiotic options to treat these bacterial infections shrink, the pressure to find new types of effective drugs increases.

October 10, 2014 | Read More

Now Accepting Submissions for Free Consultative Session and Roadmap

by Robert Buckheit

In celebration of our 10th anniversary, we are selecting candidates to receive a free consultative session, resulting in the delivery of a comprehensive drug development roadmap. For a chance to be selected, please fill out the form here.

June 10, 2014 | Read More

A Proud Day for ImQuest BioSciences!

by Robert Buckheit

Last night, the company was named one of Frederick’s Best Places to Work for 2012-2013, winning in the mid-size business category. I was at the awards ceremony at the Delaplaine Visual Arts Center in Frederick along with Dan Caffoe, Chairman, and Karen Buckheit, Director of Topical Microbicide Research and received the award on behalf of ImQuest employees. The Best Places to Work award is now in its tenth year and recognizes companies in Frederick County that offer innovative programs to recruit, train, and retain their most important asset - their staff.

August 23, 2012 | Read More